IngentaConnect Low-dose lansoprazole and clarithromycin plus metronidazole vs. f...

Authors: Bazzoli, F.¹; Zagari, R. M.¹; Pozzato, P.¹; Fossi, S.¹; Ricciardiello, L.¹; Nicolini, G.¹; De Luca, L.¹; Berretti, D.¹; Alampi, G.²; Di Pietro, C.³; Morelli, P.³; Roda, E.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 16, Number 1, January 2002 , pp. 153-158(6)

Publisher: Blackwell Publishing

Abstract:

Aim:

To compare, in a randomized controlled trial, the efficacy and tolerability of two 1-week triple therapies for Helicobacter pylori eradication. Methods:

One hundred and thirty-four consecutive patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive lansoprazole 30 mg once daily, clarithromycin 250 mg twice daily, and metronidazole 500 mg twice daily (LCM group), or lansoprazole 30 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1000 mg twice daily (LCA group). H. pylori status was assessed by rapid urease test, histology and ¹³C-urea breath test before and after therapy. Results:

At 3 months, H. pylori eradication (intention- to-treat/per protocol analysis) was 92.4%/93.8% in the LCM group and 83.1%/85.7% in the LCA group (P=N.S.). Side-effects were more frequently reported in the LCA group (37.9%) than in the LCM group (19.7%) (P < 0.05). Conclusions:

In this open, randomized controlled trial, eradication of H. pylori by low-dose lansoprazole and clarithromycin plus metronidazole was higher with significantly less side-effects than by full-dose lansoprazole and clarithromycin plus amoxicillin. This finding may be related to the stronger synergism of clarithromycin plus metronidazole, even at lower doses, than of clarithromycin plus amoxicillin. Considering the lower cost as well, LCM should be preferred to LCA in the eradication of H. pylori.

Document Type: Research article

DOI: 10.1046/j.1365-2036.2002.01141.x

Affiliations: 1: Dipartimento di Medicina Interna e Gastroenterologia, Università degli Studi di Bologna, Italy, 2: Istituto di Anatomia ed Istologia Patologica, Università degli Studi di Bologna, Italy, 3: Takeda Italia Farmaceutici S.p.A.

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on Synergy.

You may be required to register and activate access on Synergy before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection